AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

The CNBC host said that he has reminded his viewers repeatedly that when the Fed is your “enemy” you should stick to ...

Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on September 26 and set a price ...

Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In November 2021, Sanofi made a similar – but not its first – investment in AI, taking a $180 million equity stake in Franco-US start-up Owkin with another $90 million in funding for a ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...